3:56 PM
 | 
Sep 13, 2018
 |  BC Extra  |  Company News

Patient groups urge CVS to reconsider ICER-restricted formulary

At least 94 patient groups and individuals signed a letter urging CVS Health Corp. (NYSE:CVS) President and CEO Larry Merlo to reconsider a new formulary that would be restricted to drugs deemed cost effective by the Institute for Clinical and Economic Review (ICER). The formulary would allow clients to exclude from their plan any drug with a launch price that exceeds...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >